Michael P. Dube Sells 1,372 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 1,372 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $16,710.96. Following the sale, the chief accounting officer now directly owns 45,640 shares of the company’s stock, valued at approximately $555,895.20. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $12.02 on Thursday. Intellia Therapeutics, Inc. has a 1 year low of $11.34 and a 1 year high of $34.87. The company has a market capitalization of $1.22 billion, a PE ratio of -2.21 and a beta of 1.83. The business has a fifty day moving average price of $13.91 and a two-hundred day moving average price of $19.15.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.38) EPS. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Chardan Capital raised their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, November 18th. Oppenheimer reduced their target price on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 11th. William Blair reaffirmed a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. Wedbush reissued a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its holdings in Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank bought a new position in shares of Intellia Therapeutics during the 3rd quarter worth $41,000. Values First Advisors Inc. purchased a new stake in Intellia Therapeutics in the 3rd quarter worth about $54,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after acquiring an additional 794 shares during the period. Finally, KBC Group NV lifted its holdings in Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.